Arama

EISSN 2148-5607

TJG IS INDEXED IN WEB OF SCIENCE AND PUBMED IMPACT FACTOR: 1.2

Turkish Journal of Gastroenterology

PDF

HIGHLY CITED ARTICLES

HBV and HCV are the risk factors in CCA

Tan et al.

Serum resolvin levels in irritable bowel syndrome

Karatay and Gül Utku

Microbial improvement after intervention

Qian et al.

18F-FDGPET/CT in gallbladder carcinoma

Arslan et al.

Bezoar in endoscopy

Gökbulut et al.

Effect of vitamin D on CD40L gene expression in UC

Sharifi et al.

ERCP for acute cholangitis

Khamaysi and Taha

Inborn metabolic causes of fatty liver disease

Yıldız and Sivri

Gastric and small intestinal TSA

Kiremitci et al.

COVID-19 in Hepatology and Liver transplantation

Kabaçam et al.

All Title Keyword Full Text DOI

Authors

Article Type

Article Category

Year

Search Results

Total of 19 results

Ranking

Release Date Sort Sort Article Type

Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats

Gülgün Tahan, Fatih EREN, Orhan TARÇIN, Hakan AKIN, Veysel Tahan, Hülya ŞAHİN, Osman ÖZDOĞAN, Neşe İMERYÜZ, Çiğdem ÇELİKEL, Erol AVŞAR, Nurdan TÖZÜN

(Turk J Gastroenterol 2010; 21: 287-292) DOI: 10.4318/tjg.2010.0102

Abstract Full Text ( PDF) Related Articles

Are we hopefully very close to the end of HCV?

Veysel Tahan

(Turk J Gastroenterol 2014; 25: 230-231) DOI: 10.5152/tjg.2014.0009

Abstract Full Text ( PDF) Related Articles

Once spontaneous bacterial peritonitis develops, discontinue nonselective beta blockers permanently. A proposed practice change update

Veysel Tahan

(Turk J Gastroenterol 2014; 25: 232-232) DOI: 10.5152/tjg.2014.0010

Abstract Full Text ( PDF) Related Articles

Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats

Are we hopefully very close to the end of HCV?

Once spontaneous bacterial peritonitis develops, discontinue nonselective beta blockers permanently. A proposed practice change update

“Old classic cars” are hidden treasures: Colorectal cancer screening should be considered in unscreened persons over age 75

How will I know whether “an apple is ripe or rotten”? A new proposed composite algorithm to predict acute liver failure in patients with drug-induced liver injury

“Could a cup of coffee a day keep the liver doctor away?”: One cup or two or more cups of coffee per day reduces the risk of death from cirrhosis

“Actions speak louder than words”: Adenoma detection rates inversely associated with colorectal cancer and mortality

“If a fake friend stays in your vodkabulary as a stem friend”: Granulocyte colony-stimulating factor promoted stem cell therapy in severe alcoholic hepatitis

Show Me Echo – Hepatitis C: A telemedicine mentoring program for patients with hepatitis C in underserved and rural areas in Missouri as a model in developing countries

Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies

Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients

In a world of increasing resistance emerges a hope to eradicate Helicobacter pylori: Vonoprazan

Covering the Cover

To chromo or not to chromo: That is the question!

“Are we ready to change our colorectal cancer screening practice?” Traditional serrated adenomas or serrated adenomas with dysplasia should be regarded as advanced adenomas with high grade dysplasia

Allogenic adipose derived stem cells present a potential novel approach for treating refractory fistulizing Crohn’s disease

Microbiome alterations observed in liver diseases present opportunities for potential fecal transplantation

Rifaximin in treatment of patients with Irritable bowel syndrome

Stem cell therapy: a potential for the perils of pancreatitis